Portada›Viernes 5 de septiembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 5 de septiembre de 2025

Los 36 documentos que 28 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← jueves 4 de septiembre de 2025 · lunes 8 de septiembre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. ARTLARTELO BIOSCIENCES, INC.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …of one of our product candidates. We expect to continue to fund our operations primarily through utilization of our current financial resources and additional raises of capital. These conditions raise substantial doubt about our ability to continue as a going concern. We have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations, which has raised substantial doubt about our ability to continue…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …effect on our reputation, business, financial condition, results of operations, growth and ability to accomplish our strategic objectives. S-4 Table of Contents Recent Developments On July 18, 2025, we entered into an At-The-Market Offering Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (“R.F. Lafferty”) under which we may offer and sell up to $6.5 million of shares of our common stock from time to time through an “at the…
2. CLNNClene Inc.S-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …the 2024 SSCP Notes, we are required to maintain unrestricted cash and cash equivalents of at least $2.0 million to avoid acceleration of the full balance of the 2024 SSCP Notes. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. 7 To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with third parties, as…

   En el documentoContrasplit de accionestexto original ▸

   …wholly-owned subsidiary of Chelsea Worldwide Inc. On the Closing Date, Chelsea Worldwide Inc. changed its name to Clene Inc. and listed its shares of common stock on Nasdaq under the symbol “CLNN.” We effected a 1-for-20 reverse stock split of our common stock beginning with the opening of trading on July 11, 2024 (the “Reverse Stock Split”). As a result, every 20 shares of common stock issued and outstanding were automatically combined…
3. CLNNClene Inc.424B5Nueva emisión de acciones con precioEDGAR
4. DBVTDBV Technologies S.A.424B5Nueva emisión de acciones con precioEDGAR
5. MBIOMUSTANG BIO, INC.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus Supplement, as amended, and the Prospectus, and any future amendments or supplements. We entered into an At the Market Offering Agreement (the “sales agreement”) dated May 31, 2024, with H.C. Wainwright & Co., LLC (“Wainwright”), as Agent, relating to the offer and sale of shares of our common stock, par value $0.0001 per share…
6. PPBTPURPLE BIOTECH LTD.424B4Nueva emisión de acciones con precioEDGAR
7. PRAXPraxis Precision Medicines, Inc.424B5Nueva emisión de acciones con precioEDGAR
8. SLXNSilexion Therapeutics CorpS-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …any committed source of financing to meet those needs, there may be substantial doubt raised about our ability to continue as a “going concern.” Please see the explanatory paragraph under the heading “Substantial Doubt about the Company’s Ability to Continue as a Going Concern” in our independent auditors’ report on our financial statements that appear in this prospectus. Those financial statements do not include any adjustments that might result from our inability to continue…
9. SXTP60 DEGREES PHARMACEUTICALS, INC.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …election in the second quarter of 2022. On February 24, 2025, we effected a reverse stock split of our common stock at a ratio of 1-for-5. Going Concern Our independent auditors have issued a report raising substantial doubt of our ability to continue as a going concern. We anticipate that we will require additional capital to continue as a going concern and expand our operations in accordance with our current business plan. Suppliers We have quality and contract manufacturing…

   En el documentoContrasplit de accionestexto original ▸

   …Australia. S-12 60P Australia previously solely owned a Singaporean subsidiary company, 60P Singapore Pte. Ltd., which dissolved at our election in the second quarter of 2022. On February 24, 2025, we effected a reverse stock split of our common stock at a ratio of 1-for-5. Going Concern Our independent auditors have issued a report raising substantial doubt of our ability to continue as a going concern. We anticipate that we will…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …60degrees.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT (To Prospectus dated September July 12, 2024) Up to $1,397,532 Common Stock We have entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) relating to shares of our common stock offered by this prospectus supplement and the accompanying base prospectus. In accordance…
10. VBIOValion Bio, Inc.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …Company’s financial statements at December 31, 2024 and 2023, and for the years then ended, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern), which is incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance on Rosenberg Rich Baker Berman, P.A.’s report, given on the authority of such firm…

    En el documentoContrasplit de accionestexto original ▸

    …stock issuable upon exercise of the Placement Agent Warrants issued on August 21, 2025 are being registered hereunder. Reverse Stock Splits Reverse Stock Split - 2025 Effective March 7, 2025, the Company implemented a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of 1-for-17. As a result of the reverse stock split, the total number of shares of common stock held by each stockholder of the…
11. LITSLite Strategy, Inc.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …align with emerging financial technologies. Our common stock is listed on the Nasdaq Capital Market under the symbol “MEIP.” Recent Developments At the Market Sales Agreement On July 22, 2025, the Company entered into an At the Market Sales Agreement (the “Sales Agreement”) with Titan (in such capacity, the “Agent”), pursuant to which the Company may sell, from time to time, at its option, up to $100,000,000 in aggregate principal amount of an indeterminate…
12. VRDNViridian Therapeutics, Inc.\DES-3ASRCapacidad de emisión registradaEDGAR

Participaciones y control

1. INDVIndivior Pharmaceuticals, Inc.SC 13D/ACambio en participación significativaEDGAR
2. TCRTAlaunos Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
3. VALNValneva SESC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. CINGCingulate Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
2. SXTP60 DEGREES PHARMACEUTICALS, INC.8-KFin de acuerdo materialEDGAR
   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) pursuant to which the Company may, from time to time, offer and sell shares (the “ATM Shares”) of its common stock, par value $0…
3. ARTLARTELO BIOSCIENCES, INC.8-KNuevo acuerdo materialEDGAR
4. CGONCG Oncology, Inc.8-KOtros hechos relevantesEDGAR
5. CLNNClene Inc.8-KOtros hechos relevantesEDGAR
6. DBVTDBV Technologies S.A.8-KOtros hechos relevantesEDGAR
7. HCWBHCW Biologics Inc.8-KNuevo acuerdo materialEDGAR
8. IBIOiBio, Inc.8-KResultadosEDGAR
9. IBIOiBio, Inc.10-KInforme anualEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …from operations, the limited cash resources on hand and the dependence by us on our ability to obtain additional financing to fund our operations after the current cash resources are exhausted raised substantial doubt about our ability to continue as a going concern. In evaluating our ability to continue as a going concern, we took into account the potential mitigating effects of management’s previously disclosed plans to mitigate the substantial doubt about our…

   En el documentoContrasplit de accionestexto original ▸

   …website does not constitute part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference. Reverse Stock Split On November 29, 2023, we effected a reverse stock split at a ratio of one-for-twenty (1:20) shares of our Common Stock. As a result of the reverse stock split, every twenty (20) shares of our Common Stock either issued and outstanding or held by us in our…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …increase as we continue our research and development activities and conduct clinical trials. We made significant progress implementing these plans, which progress is described below. ​ On July 3, 2024, we entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with Chardan and Craig-Hallum (collectively, the “Sales Agents”) providing for the issuance and sale by us of our Common Stock, from time to time, through the Sales Agents, with certain limitations…
10. KYNBKYNTRA BIO, INC.8-KCompra o venta de activos completadaEDGAR
11. LNAILunai Bioworks Inc.8-KOtros hechos relevantesEDGAR
12. LPCNLipocine Inc.8-KOtros hechos relevantesEDGAR
13. LPCNLipocine Inc.8-KOtros hechos relevantesEDGAR
14. OCGNOcugen, Inc.8-KNuevo acuerdo materialEDGAR
15. OTLKOutlook Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
16. PALIPALISADE BIO, INC.8-KCambio en el consejo o la direcciónEDGAR
17. PMCBPharmaCyte Biotech, Inc.8-KNuevo acuerdo materialEDGAR
18. PRAXPraxis Precision Medicines, Inc.8-KOtros hechos relevantesEDGAR
19. SANASana Biotechnology, Inc.8-KCambio en el consejo o la direcciónEDGAR
20. SHPHShuttle Pharmaceuticals Holdings, Inc.8-KCambio en el consejo o la direcciónEDGAR

Juntas de accionistas

1. SILOSilo Pharma, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …Company and our shareholders and is likely to improve the trading price of our Common Stock and improve the likelihood that we will be allowed to maintain our listing on Nasdaq. Accordingly, our Board approved the Reverse Stock Split as being in the best interests of the Company. Effective Increase of Authorized and Unissued Shares Under our Charter, we are authorized to issue 100,000,000 shares of Common Stock. As of the Record Date…

← jueves 4 de septiembre de 2025 · lunes 8 de septiembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.